Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience

被引：0
|
作者：
Lorenzo Livi
Pierluigi Bonomo
Icro Meattini
Gabriele Simontacchi
Daniela Greto
Isacco Desideri
Fiammetta Meacci
Vieri Scotti
Sara Cecchini
Jacopo Nori
Luis Jose Sanchez
Lorenzo Orzalesi
Fabiola Paiar
Gianpaolo Biti
机构：
[1] University of Florence,Radiotherapy Unit, IFCA
[2] University of Florence,Radiation Oncology Department, AOUC
[3] University of Florence,Diagnostic Senology Unit
[4] University of Florence,Department of Surgery
来源：
Medical Oncology | 2013年 / 30卷
关键词：
Breast cancer; Metastatic breast carcinoma; Bevacizumab; Paclitaxel; Chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The aim of our analysis was to report the outcome and safety of patients treated with bevacizumab and paclitaxel as first-line treatment for HER2-negative metastatic breast cancer. Between February 2009 and August 2011, 62 consecutive patients received paclitaxel 90 mg/m2 on days 1, 8, and 15 and bevacizumab (BV) 10 mg/kg intravenously on days 1 and 15, every 28-day cycle. After 6 cycles of combined treatment, patients were given maintenance BV every 3 weeks (15 mg/kg) until progression disease or unacceptable toxicity. At time of analysis, median overall survival was 12.3 months (range 4.6–44.8 months), progression-free survival was 8.1 months (range 2.3–33.2 months), and time to treatment failure was 8.4 months (range 2.3–33.2 months). Our results confirmed the efficacy and the acceptable toxicity profile of bevacizumab plus paclitaxel as first-line regimen for metastatic breast cancer.
引用
收藏
相关论文
共 50 条
  • [21] Phase II study of nab-paclitaxel, bevacizumab, and gemcitabine for first-line therapy of patients with HER2-negative metastatic breast cancer (MBC)
    Gluck, S.
    Lobo, C.
    Reis, I.
    Lopes, G.
    Carmody, C.
    Tukia, K.
    Hurley, J.
    Seo, P.
    Silva, O.
    Slingerland, J.
    Welsh, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [22] PACLITAXEL (P) AND BEVACIZUMAB (BEV), AS FIRST-LINE CHEMOTHERAPY, IN PATIENTS WITH HER2-NEGATIVE METASTATIC BREAST CANCER (MBC). THE HELLENIC COOPERATIVE ONCOLOGY GROUP EXPERIENCE WITH BIOMARKER EVALUATION
    Kourea, H. P.
    Koutras, A. K.
    Kotoula, V.
    Bobos, M.
    Fountzila, A. Kalogera
    Papazisis, K. T.
    Christodoulou, C.
    Res, E.
    Bournakis, E.
    Fountzilas, G.
    ANNALS OF ONCOLOGY, 2010, 21 : 104 - 104
  • [23] Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
    Lobo, Christopher
    Lopes, Gilberto
    Baez, Odalys
    Castrellon, Aurelio
    Ferrell, Annapoorna
    Higgins, Connie
    Hurley, Erin
    Hurley, Judith
    Reis, Isildinha
    Richman, Stephen
    Seo, Pearl
    Silva, Orlando
    Slingerland, Joyce
    Tukia, Keleni
    Welsh, Catherine
    Glueck, Stefan
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 123 (02) : 427 - 435
  • [24] Biomarker study of patients with HER2-negative metastatic breast cancer receiving combination therapy with nivolumab, bevacizumab and paclitaxel as first-line treatment (WJOG9917BTR)
    Ozaki, Y.
    Kitano, S.
    Matsumoto, K.
    Takahashi, M.
    Mukohara, T.
    Futamura, M.
    Masuda, N.
    Tsurutani, J.
    Yoshimura, K.
    Minami, H.
    Takano, T.
    CANCER RESEARCH, 2019, 79 (04)
  • [25] Pooled-analysis of prospective observational studies evaluated the effectiveness and safety of bevacizumab and paclitaxel as the first-line chemotherapy for HER2-negative metastatic breast cancer
    Yamashiro, H.
    Yamamoto, Y.
    Schneeweiss, A.
    Mueller, V.
    Gluz, O.
    Klare, P.
    Aktas, B.
    Magdolna, D.
    Buedi, L.
    Piko, B.
    Mangel, L.
    Toi, M.
    Morita, S.
    Ohno, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S367 - S367
  • [26] BevacizumabA Review of its Use in Combination with Paclitaxel or Capecitabine as First-Line Therapy for HER2-Negative Metastatic Breast Cancer
    Katherine F. Croom
    Sohita Dhillon
    Drugs, 2011, 71 : 2213 - 2229
  • [27] Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
    Christopher Lobo
    Gilberto Lopes
    Odalys Baez
    Aurelio Castrellon
    Annapoorna Ferrell
    Connie Higgins
    Erin Hurley
    Judith Hurley
    Isildinha Reis
    Stephen Richman
    Pearl Seo
    Orlando Silva
    Joyce Slingerland
    Keleni Tukia
    Catherine Welsh
    Stefan Glück
    Breast Cancer Research and Treatment, 2010, 123 : 427 - 435
  • [28] Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial
    Lam, S. W.
    de Groot, S. M.
    Honkoop, A. H.
    Jager, A.
    ten Tije, A. J.
    Bos, M. M. E. M.
    Linn, S. C.
    van den Bosch, J.
    Kroep, J. R.
    Braun, J. J.
    van Tinteren, H.
    Boven, E.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (18) : 3077 - 3088
  • [29] Paclitaxel with bevacizumab (PB) as first-line therapy for metastatic breast cancer: Our experience
    Salesi, N.
    Colonna, M.
    Di Cocco, B.
    Moscato, M.
    Calogero, A.
    Pacini, L.
    Veltri, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] Bevacizumab in the treatment of HER2-negative breast cancer
    Lorusso, Vito
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (04): : 813 - 821
12345